Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cardio-renal-metabolic syndrome diseases, particularly those driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor initially aimed at treating uncontrolled hypertension and resistant hypertension in patients not achieving blood pressure goals despite multiple antihypertensive medications. The company addresses unmet needs in hypertension, chronic kidney disease, obstructive sleep apnea, and related conditions where elevated aldosterone plays a key role, offering a novel mechanism to lower aldosterone levels by inhibiting the CYP11B2 enzyme. Mineralys Therapeutics, Inc. emphasizes precision in treatment, targeting patients with indicators like obesity that suggest aldosterone dependency. Led by an experienced management team and supported by expert scientific and board advisors in cardiovascular and renal diseases, the company advances its pipeline through clinical development. Founded in 2019 and headquartered in Radnor, Pennsylvania, Mineralys Therapeutics, Inc. plays a significant role in the biotechnology sector by innovating solutions for prevalent cardiometabolic disorders affecting millions worldwide.